Research ExplorerPublicationsEfficacy of low-dose mTHPC-PDT for the treatment of basal ce...

Efficacy of low-dose mTHPC-PDT for the treatment of basal cell carcinomas

Standard

Efficacy of low-dose mTHPC-PDT for the treatment of basal cell carcinomas. / Betz, Christian S.; Rauschning, Winrich; Stranadko, Evgueni P.; Riabov, Mikhail V.; Albrecht, Volker; Nifantiev, Nikolay E.; Hopper, Colin.

12TH WORLD CONGRESS OF THE INTERNATIONAL PHOTODYNAMIC ASSOCIATION: PHOTODYNAMIC THERAPY: BACK TO THE FUTURE. ed. / DH Kessel. Vol. 7380 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA : SPIE-INT SOC OPTICAL ENGINEERING, 2009. (Proceedings of SPIE).

Research output: SCORING: Contribution to book/anthology › SCORING: Contribution to collected editions/anthologies › Research › peer-review

Harvard

Betz, CS, Rauschning, W, Stranadko, EP, Riabov, MV, Albrecht, V, Nifantiev, NE & Hopper, C 2009, Efficacy of low-dose mTHPC-PDT for the treatment of basal cell carcinomas. in DH Kessel (ed.), 12TH WORLD CONGRESS OF THE INTERNATIONAL PHOTODYNAMIC ASSOCIATION: PHOTODYNAMIC THERAPY: BACK TO THE FUTURE. vol. 7380, Proceedings of SPIE, SPIE-INT SOC OPTICAL ENGINEERING, 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA. https://doi.org/10.1117/12.822063

APA

Betz, C. S., Rauschning, W., Stranadko, E. P., Riabov, M. V., Albrecht, V., Nifantiev, N. E., & Hopper, C. (2009). Efficacy of low-dose mTHPC-PDT for the treatment of basal cell carcinomas. In DH. Kessel (Ed.), 12TH WORLD CONGRESS OF THE INTERNATIONAL PHOTODYNAMIC ASSOCIATION: PHOTODYNAMIC THERAPY: BACK TO THE FUTURE (Vol. 7380). (Proceedings of SPIE). SPIE-INT SOC OPTICAL ENGINEERING. https://doi.org/10.1117/12.822063

Vancouver

Betz CS, Rauschning W, Stranadko EP, Riabov MV, Albrecht V, Nifantiev NE et al. Efficacy of low-dose mTHPC-PDT for the treatment of basal cell carcinomas. In Kessel DH, editor, 12TH WORLD CONGRESS OF THE INTERNATIONAL PHOTODYNAMIC ASSOCIATION: PHOTODYNAMIC THERAPY: BACK TO THE FUTURE. Vol. 7380. 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA: SPIE-INT SOC OPTICAL ENGINEERING. 2009. (Proceedings of SPIE). https://doi.org/10.1117/12.822063

Bibtex

@inbook{000c7e158e404c018beb52944121e7af,
title = "Efficacy of low-dose mTHPC-PDT for the treatment of basal cell carcinomas",
abstract = "Objectives: Basal cell carcinomas (BCCs) are the most common skin cancers, and incidence rates are still rising. Photodynamic Therapy (PDT) with mTHPC (Foscan (R)) has shown to be a promising alternative to other treatments with good cosmetic results. This study was performed to determine optimal treatment parameters for this indication. Methods: 117 patients with a total of 460 BCCs received mTHPC-PDT. The treatment parameters were varied as follows: Foscan (R) dose 0.03 - 0.15 mg/kg, drug-light interval (DLI) 1 - 96 hours, total energy density 20 -120 J/cm2. The clinical outcomes were assessed 8 weeks after PDT following WHO guidelines. Results: The rate of complete remissions (CR) was 96.7% and the general cosmetic outcome rated very good. In the largest subgroup (n=80) with low-dose mTHPC (0.05 mg/kg mTHPC; 48 hours DLI; 50 J/cm2 total energy density), a CR rate of 100% was accomplished. Minor changes of the parameters (0.04 mg/kg mTHPC or 24 hours DLI) yielded similar results. Side effects were encountered in 52 out of 133 PDT sessions. They were more common in patients who had received high drug doses (0.06 - 0.15 mg/kg) and comprised pain and phototoxic reactions. 3 patients developed severe sunburns with subsequent scarring at the injection site following sunlight exposure 2-3 weeks after mTHPC administration. Conclusions: The data suggests that low-dose mTHPC-PDT is an effective treatment option for BCCs. If sensibly applied, it is well tolerated and provides mostly excellent cosmetic results. The evaluation of long term results is still to be undertaken.",
keywords = "photodynamic therapy, basal cell carcinoma, mTHPC",
author = "Betz, {Christian S.} and Winrich Rauschning and Stranadko, {Evgueni P.} and Riabov, {Mikhail V.} and Volker Albrecht and Nifantiev, {Nikolay E.} and Colin Hopper",
note = "12th World Congress of the International-Photodynamic-Association (IPA) on Photodynamic Therapy - Back to the Future, Seattle, WA, JUN 11-15, 2009",
year = "2009",
doi = "10.1117/12.822063",
language = "English",
isbn = "978-0-8194-7660-9",
volume = "7380",
series = "Proceedings of SPIE",
publisher = "SPIE-INT SOC OPTICAL ENGINEERING",
editor = "DH Kessel",
booktitle = "12TH WORLD CONGRESS OF THE INTERNATIONAL PHOTODYNAMIC ASSOCIATION: PHOTODYNAMIC THERAPY: BACK TO THE FUTURE",

}

RIS

TY - CHAP

T1 - Efficacy of low-dose mTHPC-PDT for the treatment of basal cell carcinomas

AU - Betz, Christian S.

AU - Rauschning, Winrich

AU - Stranadko, Evgueni P.

AU - Riabov, Mikhail V.

AU - Albrecht, Volker

AU - Nifantiev, Nikolay E.

AU - Hopper, Colin

N1 - 12th World Congress of the International-Photodynamic-Association (IPA) on Photodynamic Therapy - Back to the Future, Seattle, WA, JUN 11-15, 2009

PY - 2009

Y1 - 2009

N2 - Objectives: Basal cell carcinomas (BCCs) are the most common skin cancers, and incidence rates are still rising. Photodynamic Therapy (PDT) with mTHPC (Foscan (R)) has shown to be a promising alternative to other treatments with good cosmetic results. This study was performed to determine optimal treatment parameters for this indication. Methods: 117 patients with a total of 460 BCCs received mTHPC-PDT. The treatment parameters were varied as follows: Foscan (R) dose 0.03 - 0.15 mg/kg, drug-light interval (DLI) 1 - 96 hours, total energy density 20 -120 J/cm2. The clinical outcomes were assessed 8 weeks after PDT following WHO guidelines. Results: The rate of complete remissions (CR) was 96.7% and the general cosmetic outcome rated very good. In the largest subgroup (n=80) with low-dose mTHPC (0.05 mg/kg mTHPC; 48 hours DLI; 50 J/cm2 total energy density), a CR rate of 100% was accomplished. Minor changes of the parameters (0.04 mg/kg mTHPC or 24 hours DLI) yielded similar results. Side effects were encountered in 52 out of 133 PDT sessions. They were more common in patients who had received high drug doses (0.06 - 0.15 mg/kg) and comprised pain and phototoxic reactions. 3 patients developed severe sunburns with subsequent scarring at the injection site following sunlight exposure 2-3 weeks after mTHPC administration. Conclusions: The data suggests that low-dose mTHPC-PDT is an effective treatment option for BCCs. If sensibly applied, it is well tolerated and provides mostly excellent cosmetic results. The evaluation of long term results is still to be undertaken.

AB - Objectives: Basal cell carcinomas (BCCs) are the most common skin cancers, and incidence rates are still rising. Photodynamic Therapy (PDT) with mTHPC (Foscan (R)) has shown to be a promising alternative to other treatments with good cosmetic results. This study was performed to determine optimal treatment parameters for this indication. Methods: 117 patients with a total of 460 BCCs received mTHPC-PDT. The treatment parameters were varied as follows: Foscan (R) dose 0.03 - 0.15 mg/kg, drug-light interval (DLI) 1 - 96 hours, total energy density 20 -120 J/cm2. The clinical outcomes were assessed 8 weeks after PDT following WHO guidelines. Results: The rate of complete remissions (CR) was 96.7% and the general cosmetic outcome rated very good. In the largest subgroup (n=80) with low-dose mTHPC (0.05 mg/kg mTHPC; 48 hours DLI; 50 J/cm2 total energy density), a CR rate of 100% was accomplished. Minor changes of the parameters (0.04 mg/kg mTHPC or 24 hours DLI) yielded similar results. Side effects were encountered in 52 out of 133 PDT sessions. They were more common in patients who had received high drug doses (0.06 - 0.15 mg/kg) and comprised pain and phototoxic reactions. 3 patients developed severe sunburns with subsequent scarring at the injection site following sunlight exposure 2-3 weeks after mTHPC administration. Conclusions: The data suggests that low-dose mTHPC-PDT is an effective treatment option for BCCs. If sensibly applied, it is well tolerated and provides mostly excellent cosmetic results. The evaluation of long term results is still to be undertaken.

KW - photodynamic therapy

KW - basal cell carcinoma

KW - mTHPC

U2 - 10.1117/12.822063

DO - 10.1117/12.822063

M3 - SCORING: Contribution to collected editions/anthologies

SN - 978-0-8194-7660-9

VL - 7380

T3 - Proceedings of SPIE

BT - 12TH WORLD CONGRESS OF THE INTERNATIONAL PHOTODYNAMIC ASSOCIATION: PHOTODYNAMIC THERAPY: BACK TO THE FUTURE

A2 - Kessel, DH

PB - SPIE-INT SOC OPTICAL ENGINEERING

CY - 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA

ER -